Welcome to our dedicated page for Black Diamond Therapeutics news (Ticker: BDTX), a resource for investors and traders seeking the latest updates and insights on Black Diamond Therapeutics stock.
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in cancer. The company’s news flow centers on the development of its lead program, silevertinib (also known as BDTX-1535), a brain-penetrant fourth-generation EGFR MasterKey inhibitor being studied in EGFR-mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
On this page, readers can follow company announcements related to clinical trial progress, including Phase 2 data updates in frontline NSCLC patients with non-classical EGFR mutations and investigator-sponsored studies in EGFR-altered GBM. Black Diamond’s releases describe objective response rates, CNS activity, duration of treatment or response, and plans for randomized Phase 2 trials in newly diagnosed GBM patients.
News items also cover corporate and financial updates, such as quarterly and annual financial results, cash runway commentary, and strategic priorities around advancing silevertinib. In addition, Black Diamond reports on business development activities, including a global licensing agreement with Servier for BDTX-4933, a Phase 1 therapy designed to target RAF/RAS-mutant solid tumors.
Investors and observers can use this news feed to track webcast and conference presentations, regulatory and development plans in NSCLC and GBM, and partnership discussions around pivotal development. Regular updates provide insight into how Black Diamond Therapeutics is progressing its MasterKey therapies across genetically defined tumor types and CNS-involved disease.
Black Diamond Therapeutics announced that its CEO, David M. Epstein, will present at the BMO Biopharma Spotlight Series on February 18, 2021, at 11:50 AM ET. The focus will be on innovative protein technologies. The presentation can be accessed via a live webcast on the company's investor relations page, with a replay available for three weeks. Black Diamond is known for pioneering tumor-agnostic therapies targeting genetically defined cancers using their unique MAP platform, which identifies oncogenic mutations across tumor types.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) has appointed Dr. Kapil Dhingra to its Board of Directors, enhancing its oncology expertise. Dr. Dhingra, with over 30 years in drug development, previously led key oncology projects at Roche. His insights are expected to be crucial for advancing the company’s candidate therapies, including BDTX-189 and BDTX-1535. The company aims to innovate in precision oncology targeting undrugged mutations to benefit patients with genetically defined cancers.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) has announced that its President and CEO, David M. Epstein, Ph.D., will present an update on the company's progress at the J.P. Morgan 39th Annual Virtual Healthcare Conference. The presentation is scheduled for January 12, 2021, at 7:30 AM ET. A live webcast will be available on the company's investor relations website, with a replay lasting three weeks. Black Diamond focuses on precision oncology, targeting undrugged mutations in genetically defined cancers via its MAP platform.
Black Diamond Therapeutics, a precision oncology medicine company, announced that its CEO, David M. Epstein, will present an update on the company's advancements at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The presentation will be available via webcast starting at the conference's beginning and archived for three weeks on the company’s investor relations website. Black Diamond integrates its proprietary Mutation-Allostery-Pharmacology platform to discover small molecule therapies targeting genetically defined cancers.
Black Diamond Therapeutics (Nasdaq: BDTX) has nominated BDTX-1535 as a development candidate for treating glioblastoma multiforme (GBM), initiating IND-enabling studies. Pre-clinical data presented at the 2020 Society for Neuro-Oncology Annual Meeting shows that BDTX-1535 effectively inhibits various oncogenic EGFR mutations linked to GBM and can penetrate the blood-brain barrier. These findings support BDTX-1535's potential to transform GBM treatment, marking a significant step in Black Diamond's commitment to innovative cancer therapies.
Black Diamond Therapeutics (Nasdaq: BDTX) announced that David M. Epstein, Ph.D., President and CEO, will present at the Jefferies 2020 Virtual London Healthcare Conference. The event occurs on November 18, 2020, at 2:40 PM GMT/9:40 AM ET. The presentation will focus on the company's progress in developing precision oncology therapies targeting genetically defined cancers.
A live webcast is accessible via their investor relations page, with a replay available for three weeks post-event.
Black Diamond Therapeutics (Nasdaq: BDTX) reported significant progress in its Phase 1/2 clinical trial of BDTX-189, with the Phase 1 portion expected to complete by mid-2021. Financially, the company holds $333.1 million in cash as of September 30, 2020, sufficient to fund operations into 2023. The company also appointed Robert A. Ingram as Chairman and Rachel Humphrey, M.D., as Chief Medical Officer, enhancing its leadership. R&D expenses have increased to $12.9 million, reflecting growth initiatives.
Black Diamond Therapeutics (Nasdaq: BDTX) reported promising pre-clinical results for its lead candidate, BDTX-189, at the 32nd EORTC-NCI-AACR Virtual Symposium. The data indicate BDTX-189 can inhibit allosteric EGFR and HER2 mutations while sparing wild-type EGFR, potentially reducing toxicity. BDTX-189 showed effective tumor regression in various models, including patient-derived xenografts. The candidate is advancing to Phase 1/2 clinical trials (MasterKey-01) in patients with advanced solid tumors. BDTX-189 has received Fast Track designation from the FDA for specific mutations in solid tumors.
Black Diamond Therapeutics (Nasdaq: BDTX) announced the presentation of pre-clinical data for its lead candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics on October 25, 2020. BDTX-189 is designed as an irreversible small molecule inhibitor targeting oncogenic mutations in EGFR and HER2. This presentation may offer insights into treating genetically defined cancers, as no FDA-approved therapies currently exist for these specific mutations. The findings could represent a significant advancement in precision oncology.
Black Diamond Therapeutics (Nasdaq: BDTX) has announced the appointment of Robert A. Ingram as Chairman of its Board of Directors, succeeding founding Chairman Brad Bolzon, who will remain on the board. Ingram, a seasoned leader in the pharmaceutical industry with experience at GlaxoWellcome and GlaxoSmithKline, is expected to steer the company towards its goal of advancing precision oncology therapies. Black Diamond possesses a proprietary MAP platform aimed at targeting genetically defined cancers. The company is committed to transforming the oncology landscape through innovative small molecule therapies.